https://doi.org/10.4081/reumatismo.2021.1406

Subclinical TRAPS treated with canakinumab

Vol. 73 No. 2 (2021)
Published: August 3 2021
TRAPS, IL-1, canakinumab, AA amyloidosis.
Abstract Views: 2624
PDF: 550
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Amatruda
https://orcid.org/0000-0001-9232-777X
Pediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina University, Italy.
N.S. Carucci
https://orcid.org/0000-0001-9642-7823
Pediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina University, Italy.
C. Fede
Pediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina University, Italy.
G. Conti
giovanniconti@hotmail.com
https://orcid.org/0000-0002-0617-500X
Pediatric Nephrology and Rheumatology Unit with Dialysis, Department of Human Pathology in Adulthood and Childhood “G. Barresi”; AOU Policlinic “G. Martino”, Messina University, Italy.

Tumor necrosis factor receptor–associated periodic syndrome (TRAPS) is a rare autoinflammatory disease characterized by recurrent episodes of fever and systemic inflammation. We describe the case of a 19-year-old patient who was referred to our attention with frequent subclinical TRAPS episodes characterized by mild arthralgias and crampy abdominal pain, without fever. Inflammatory markers, including serum amyloid A which increases the risk of long-term amyloidosis, were persistently high also when the patient was in good general conditions. Therapy with human anti-interleukin 1β monoclonal antibody, canakinumab, led to disease control and normalization of the inflammatory markers, which are currently still normal. This clinical case supports the need to treat also subclinical TRAPS. In this respect, canakinumab is effective and reduces the risk of developing amyloidosis.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017; 31: 596-609. DOI: https://doi.org/10.1016/j.berh.2017.12.001
Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014; 73: 2160-7. DOI: https://doi.org/10.1136/annrheumdis-2013-204184
Gattorno M, Hofer M, Federici S, et al. Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO). Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019; 78: 1025-1032. DOI: https://doi.org/10.1136/annrheumdis-2019-215048
Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017; 76: 173-178. DOI: https://doi.org/10.1136/annrheumdis-2015-209031
De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018; 378: 1908-1919. DOI: https://doi.org/10.1056/NEJMoa1706314
Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011; 63: 314-24. DOI: https://doi.org/10.1002/art.30105
Miyamae T, Hanaya A, Kawamoto M, et al. Diagnostic rate of autoinflammatory diseases evaluated by fever patterns in pediatric- and adult-onset patients. J Clin Rheumatol. 2020; 26: 60-62. DOI: https://doi.org/10.1097/RHU.0000000000000929
Procopio V, Manti S, Bianco G, et al. Genotype-phenotype correlation in FMF patients: A "non classic" recessive autosomal or "atypical" dominant autosomal inheritance?. Gene. 2018; 641: 279-286. DOI: https://doi.org/10.1016/j.gene.2017.10.068
Quillinan N, Mohammad A, Mannion G, et al. Imaging evidence for persistent subclinical fasciitis and arthritis in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) between febrile attacks. Ann Rheum Dis. 2010; 69: 1408-9. DOI: https://doi.org/10.1136/ard.2009.118661
Kallinich T, Haffner D, Rudolph B, et al. "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis. 2006; 65: 958-60. DOI: https://doi.org/10.1136/ard.2005.043570
Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol. 2004; 31: 2519-22. DOI: https://doi.org/10.1055/s-2003-45080
Scarpioni R, Ricardi M, Albertazzi V. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. World J Nephrol. 2016; 5: 66-75. DOI: https://doi.org/10.5527/wjn.v5.i1.66

How to Cite



Subclinical TRAPS treated with canakinumab. (2021). Reumatismo, 73(2), 131-134. https://doi.org/10.4081/reumatismo.2021.1406

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.